Single Cell RNA Sequencing Identifies Subsets of Hepatic Stellate Cells and Myofibroblasts in Liver Fibrosis
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Activation of hepatic stellate cells (HSCs) and their trans-differentiation towards collagen-secreting myofibroblasts (MFB) promote liver fibrosis progression. During chronic liver disease, resting HSCs become activated by inflammatory and injury signals. However, HSCs/MFB not only produce collagen, but also secrete cytokines, participate in metabolism, and have biomechanical properties. We herein aimed to characterize the heterogeneity of these liver mesenchymal cells by single cell RNA sequencing. In vivo resting HSCs or activated MFB were isolated from C57BL6/J mice challenged by carbon tetrachloride (CCl4) intraperitoneally for 3 weeks to induce liver fibrosis and compared to in vitro cultivated MFB. While resting HSCs formed a homogenous population characterized by high platelet derived growth factor receptor β (PDGFRβ) expression, in vivo and in vitro activated MFB split into heterogeneous populations, characterized by α-smooth muscle actin (α-SMA), collagens, or immunological markers. S100 calcium binding protein A6 (S100A6) was a universal marker of activated MFB on both the gene and protein expression level. Compared to the heterogeneity of in vivo MFB, MFB in vitro sequentially and only transiently expressed marker genes, such as chemokines, during culture activation. Taken together, our data demonstrate the heterogeneity of HSCs and MFB, indicating the existence of functionally relevant subsets in hepatic fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ScRNA-seq allows for high-resolution transcriptomic profiling of mesenchymal subpopulations during liver fibrosis, revealing that chemokine/cytokine release and extracellular matrix production are diversified among HSC/myofibroblast subpopulations owing to a higher degree of cellular heterogeneity than previously appreciated.109–111”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [110]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Fcna (a marker of quiescent hepatic stellate cells 53 )”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [53]
In the citing paper
“scRNAseq data from mouse fibrosis models revealed that chemokine/cytokine release and ECM production appears to be diversified between HSC/myofibroblast subpopulations.130”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [130]
In the citing paper
“Unbiased cross-species mapping of scRNAseq data using canonical correlation analysis (CCA)21 confirmed that murine and human scar-associated macrophages represent corollary populations.”
From Fibrosis: from mechanisms to medicines (2020) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909 · cited 1×
“Upregulated expression of chemokines, such as CCL2, CXCL1, or CXCL12, and collagens, particularly COL1A2, COL3A1, or COL5A2, are often named attributes for activated MFB [13].”
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965 · cited 1×
“Liver fibrosis is also considered as a cornerstone event in the progression toward liver cirrhosis or hepatocellular carcinoma [15].”
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations
MacParland, S. A., Liu, J. C., Ma, X.-Z., Innes, B. T., Bartczak, A. M., Gage, B. K., Manuel, J., Khuu, N., Echeverri, J., Linares, I., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06318-7 · Cited by 1,552
Hepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485 · cited 1×
“Preventing or reversing excessive hepatic scarring is a major therapeutic target in treating chronic liver diseases, such as viral hepatitis and alcoholic and non-alcoholic steatohepatitis [2].”
Pathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894 · cited 1×
“The upregulation of collagens and α-SMA in MFB is a well-established finding [16] and was confirmed by our single-cell based data for MFB in vivo as well as in vitro.”
Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications
Weiskirchen, R., Weiskirchen, S., & Tacke, F. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.003 · Cited by 538 · cited 1×
“At present, α-SMA is largely accepted as a marker of activated MFB [12].”
Self-citationInflammatory macrophages can transdifferentiate into myofibroblasts during renal fibrosis
Meng, X.-M., Wang, S., Huang, X.-R., Yang, C., Xiao, J., Zhang, Y., To, K.-F., Nikolic-Paterson, D. J., & Lan, H.-Y. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.402 · Cited by 325 · cited 2×
“Due to the combination of characteristics of myeloid leukocytes, as well as of myofibroblasts, cluster MFB II most likely includes trans-differentiated myeloid myofibroblasts, which have been described before [11].”
Weiskirchen, R., & Tacke, F. (2014) · PubMed · doi:10.3978/j.issn.2304-3881.2014.11.03 · Cited by 256 · cited 3×
“, contraction and vascular resistance regulation in the liver), and lipid metabolism to immune regulation [4], raising the question about yet unrecognized, functionally diverse subsets of HSCs/MFB.”
Self-citation
Cited by
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
“Interestingly, even fibrotic livers contain a population of HSCs with a resting (or probably weakly activated) phenotype that express various growth factors and cytokines and suppress liver inflammation and fibrosis 158,159 .”
Self-citationWound healing, fibroblast heterogeneity, and fibrosis
Talbott, H. E., Mascharak, S., Griffin, M., Wan, D. C., & Longaker, M. T. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.07.006 · Cited by 795
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.311 · Cited by 671
Cancer-associated fibroblasts in the single-cell era
Lavie, D., Ben-Shmuel, A., Erez, N., & Scherz-Shouval, R. (2022) · Nature Cancer · doi:10.1038/s43018-022-00411-z · Cited by 616
The Power of Plasticity—Metabolic Regulation of Hepatic Stellate Cells
Trivedi, P., Wang, S., & Friedman, S. L. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.026 · Cited by 427
“As with many features of HSCs, the cells are heterogenous with respect to retinoid content (D’Ambrosio et al., 2011; Krenkel et al., 2019).”
BackgroundSingle-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis
Dobie, R., Wilson-Kanamori, J. R., Henderson, B. E. P., Smith, J. R., Matchett, K. P., Portman, J. R., Wallenborg, K., Picelli, S., Zagorska, A., Pendem, S. V., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.024 · Cited by 420
“HSC zonation has previously been described in porcine liver (Wake and Sato, 1993), and a recent scRNA-seq study in mice concluded that HSCs from healthy liver are a transcriptionally homogeneous population (Krenkel et al., 2019).”
BackgroundAn integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citationLiver regeneration and inflammation: from fundamental science to clinical applications
Campana, L., Esser, H., Huch, M., & Forbes, S. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00373-7 · Cited by 307
Pakshir, P., Noskovicova, N., Lodyga, M., Son, D. O., Schuster, R., Goodwin, A., Karvonen, H., & Hinz, B. (2020) · Journal of Cell Science · doi:10.1242/jcs.227900 · Cited by 293
Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis
Ramachandran, P., Matchett, K. P., Dobie, R., Wilson-Kanamori, J. R., & Henderson, N. C. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0304-x · Cited by 253
Cellular Mechanisms of Liver Fibrosis
Acharya, P., Chouhan, K., Weiskirchen, S., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671640 · Cited by 252
Self-citationXie, Q., Liu, R., Jiang, J., Peng, J., Yang, C., Zhang, W., Wang, S., & Song, J. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02011-z · Cited by 252
“The activation of hepatic stellate cells (HSCs) is a critical element of the etiology of hepatic fibrosis [28], which can be inhibited by HUC-MSCs.”
BackgroundYang, W., He, H., Wang, T., Su, N., Zhang, F., Jiang, K., Zhu, J., Zhang, C., Niu, K., Wang, L., et al. (2021) · Hepatology · doi:10.1002/hep.31987 · Cited by 250
Identification, discrimination and heterogeneity of fibroblasts
Lendahl, U., Muhl, L., & Betsholtz, C. (2022) · Nature Communications · doi:10.1038/s41467-022-30633-9 · Cited by 239
Chen, K., Wang, Q., Li, M., Guo, H., Liu, W., Wang, F., Tian, X., & Yang, Y. (2021) · eBioMedicine · doi:10.1016/j.ebiom.2021.103315 · Cited by 229
Impact of the Human Cell Atlas on medicine
Rood, J. E., Maartens, A., Hupalowska, A., Teichmann, S. A., & Regev, A. (2022) · Nature Medicine · doi:10.1038/s41591-022-02104-7 · Cited by 222
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 218
The bright side of fibroblasts: molecular signature and regenerative cues in major organs
Gomes, R. N., Manuel, F., & Nascimento, D. S. (2021) · npj Regenerative Medicine · doi:10.1038/s41536-021-00153-z · Cited by 156
Fibrosis in IBD: from pathogenesis to therapeutic targets
Rieder, F., Mukherjee, P. K., Massey, W. J., Wang, Y., & Fiocchi, C. (2024) · Gut · doi:10.1136/gutjnl-2023-329963 · Cited by 185
“…type ( Pdgfrb high ) in lung fibrosis, 38 heterogeneity of hepatic stellate cells (HSC), ACKR1+ and PLVAP+ endothelial cells and PDGFR α + collagen-producing myofibroblasts in liver fibrosis, 39–42 and the contribution of monocytes to the pool of myofibroblasts (PDGFR β + CD45+) in kidney fibrosis.”
BackgroundTacke, F., & Weiskirchen, R. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4354 · Cited by 173
Self-citationFriend or foe? The elusive role of hepatic stellate cells in liver cancer
Cogliati, B., Yashaswini, C. N., Wang, S., Sia, D., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00821-z · Cited by 148
“In a healthy liver, initial scRNA-seq studies found only one HSC population 55,56 , whereas in injury, there are at least two subpopulations of HSCs based on the expression of genes related to retinoid storage and myofibro-blast function, which roughly correspond to quiescent and activated HSCs,…”
BackgroundThe inflammatory speech of fibroblasts
Schuster, R., Rockel, J. S., Kapoor, M., & Hinz, B. (2021) · Immunological Reviews · doi:10.1111/imr.12971 · Cited by 172
Su, Q., Kim, S. Y., Adewale, F., Zhou, Y., Aldler, C., Ni, M., Wei, Y., Burczynski, M. E., Atwal, G. S., Sleeman, M. W., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103233 · Cited by 149
Acute liver failure is regulated by MYC- and microbiome-dependent programs
Kolodziejczyk, A. A., Federici, S., Zmora, N., Mohapatra, G., Dori-Bachash, M., Hornstein, S., Leshem, A., Reuveni, D., Zigmond, E., Tobar, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1102-2 · Cited by 153
Multipotent stromal cells: One name, multiple identities
Soliman, H., Theret, M., Scott, W., Hill, L., Underhill, T. M., Hinz, B., & Rossi, F. M. V. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.09.001 · Cited by 147
Heterogeneity of HSCs in a Mouse Model of NASH
Rosenthal, S. B., Liu, X., Ganguly, S., Dhar, D., Pasillas, M. P., Ricciardelli, E., Li, R. Z., Troutman, T. D., Kisseleva, T., Glass, C. K., et al. (2021) · Hepatology · doi:10.1002/hep.31743 · Cited by 145
Novel mechanisms and clinical trial endpoints in intestinal fibrosis*
Wang, J., Lin, S., Brown, J. M., van Wagoner, D., Fiocchi, C., & Rieder, F. (2021) · Immunological Reviews · doi:10.1111/imr.12974 · Cited by 115
Savage, T. M., Fortson, K. T., de los Santos-Alexis, K., Oliveras-Alsina, A., Rouanne, M., Rae, S. S., Gamarra, J. R., Shayya, H., Kornberg, A., Cavero, R., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.009 · Cited by 120
Understanding the cellular interactome of non-alcoholic fatty liver disease
Wallace, S. J., Tacke, F., Schwabe, R. F., & Henderson, N. C. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100524 · Cited by 116
Self-citationTranscriptional Dynamics of Hepatic Sinusoid‐Associated Cells After Liver Injury
Terkelsen, M. K., Bendixen, S. M., Hansen, D., Scott, E. A. H., Moeller, A. F., Nielsen, R., Mandrup, S., Schlosser, A. G., Andersen, T. L., Sørensen, G. L., et al. (2020) · Hepatology · doi:10.1002/hep.31215 · Cited by 114
“Recent studies include one establishing HSC zonation as a determinant of the fibrotic response,(14) one detailing cellular crosstalk in murine nonalcoholic steatohepatitis (NASH) resolving endothelial and macrophage populations(15) and one demonstrating HSC heterogeneity in the injured liver but offering limited resol…”
BackgroundInsights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Arrese, M., Arab, J. P., Barrera, F., Kaufmann, B., Valenti, L., & Feldstein, A. E. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730927 · Cited by 103
Understanding the heterogeneity of resident liver macrophages
Blériot, C., & Ginhoux, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02694 · Cited by 107
“A most recent contribution has focused on the heterogeneity of HSCs, quiescent at steady-state or activated in a chemically induced model of fibrosis (37).”
BackgroundInflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies
Lee, Y. A., & Friedman, S. L. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13380 · Cited by 108
Myofibroblast YAP/TAZ activation is a key step in organ fibrogenesis
He, X., Tolosa, M. F., Zhang, T., Goru, S. K., Ulloa Severino, L., Misra, P. S., McEvoy, C. M., Caldwell, L., Szeto, S. G., Gao, F., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.146243 · Cited by 106
“C), and CCl4-induced liver fibrosis (Figure 5, D and E).”
MethodInfluentialSingle-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis
Wang, Z.-Y., Keogh, A., Waldt, A., Cuttat, R., Neri, M., Zhu, S., Schuierer, S., Ruchti, A., Crochemore, C., Knehr, J., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98806-y · Cited by 103
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis
Knorr, J., Kaufmann, B., Inzaugarat, M. E., Holtmann, T. M., Geisler, L., Hundertmark, J., Kohlhepp, M. S., Boosheri, L. M., Chilin‐Fuentes, D. R., Birmingham, A., et al. (2023) · Hepatology · doi:10.1002/hep.32776 · Cited by 92
Self-citationWang, S., Tang, X. T., Lin, M., Yuan, J., Peng, Y. J., Yin, X., Shang, G., Ge, G., Ren, Z., & Zhou, B. O. (2021) · Hepatology · doi:10.1002/hep.31848 · Cited by 89
“Our lineage- tracing data are consistent with the transcriptional and functional heterogeneity of HSCs revealed by scRNAseq.(12,13,22) Thus, HSCs are not a homogenous population.”
ResultIdentifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma
Zhang, J., Gu, C., Song, Q., Zhu, M., Xu, Y., Xiao, M., & Zheng, W. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00488-y · Cited by 96
“Recently, the subtypes and biological functions of CAF are analyzed precisely by using more advanced technologies, such as single-cell sequencing and flow cytometry [29].”
MethodLei, L., Bruneau, A., El Mourabit, H., Guégan, J., Folseraas, T., Lemoinne, S., Karlsen, T. H., Hoareau, B., Morichon, R., Gonzalez‐Sanchez, E., et al. (2022) · Hepatology · doi:10.1002/hep.32456 · Cited by 94
Self-citationDissecting Fibroblast Heterogeneity in Health and Fibrotic Disease
Shaw, T. J., & Rognoni, E. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00903-w · Cited by 94
Angiocrine signaling in sinusoidal homeostasis and liver diseases
Gao, J., Lan, T., Kostallari, E., Guo, Y., Lai, E., Guillot, A., Ding, B., Tacke, F., Tang, C., & Shah, V. H. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.014 · Cited by 90
Self-citationPuengel, T., De Vos, S., Hundertmark, J., Kohlhepp, M., Guldiken, N., Pujuguet, P., Auberval, M., Marsais, F., Shoji, K. F., Saniere, L., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041140 · Cited by 85
“Moreover, expression of GPR84 was not detectable on hepatic stellate cells (HSC), the key matrix-producing cell type responsible of liver fibrosis progression [9,31], supporting that the antifibrotic effects of GPR84 antagonists were related to their inhibition of myeloid cells (and not HSC directly).”
BackgroundSelf-citationRegulation of Hepatic Stellate Cell Phenotypes in Metabolic Dysfunction–Associated Steatohepatitis
Kisseleva, T., Ganguly, S., Murad, R., Wang, A., & Brenner, D. A. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.03.010 · Cited by 85
New drugs for NAFLD: lessons from basic models to the clinic
Reimer, K. C., Wree, A., Roderburg, C., & Tacke, F. (2019) · Hepatology International · doi:10.1007/s12072-019-10001-4 · Cited by 84
“HSC transdifferentiation, however, involves a number of complex intra- and extracellular signals provided by chemokines, macrophages, surrounding hepatocytes, cell metabolism, and has been extensively studied over the years [19, 62].”
BackgroundSelf-citationNoordijk, B., García‐Gómez, M. L., ten Tusscher, K., de Ridder, D., van Dijk, A. D. J., & Smith, R. W. (2024) · Frontiers in Systems Biology · doi:10.3389/fsysb.2024.1407994 · Cited by 85
Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease
Wiering, L., Subramanian, P., & Hammerich, L. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.02.010 · Cited by 80
Gut-liver axis: Recent concepts in pathophysiology in alcohol-associated liver disease
Raya Tonetti, F., Eguileor, A., Mrdjen, M., Pathak, V., Travers, J., Nagy, L. E., & Llorente, C. (2024) · Hepatology · doi:10.1097/hep.0000000000000924 · Cited by 78
Initiation of hepatic stellate cell activation extends into chronic liver disease
De Smet, V., Eysackers, N., Merens, V., Kazemzadeh Dastjerd, M., Halder, G., Verhulst, S., Mannaerts, I., & van Grunsven, L. A. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04377-1 · Cited by 78
“To distinguish between these possibilities, we analyzed single cell (sc) RNASeq data from HSCs isolated from mice treated with CCl4 for 3 weeks [24].”
MethodIn Vitro Models for the Study of Liver Biology and Diseases: Advances and Limitations
Kaur, S., Kidambi, S., Ortega-Ribera, M., Thuy, L. T. T., Nieto, N., Cogger, V. C., Xie, W.-F., Tacke, F., & Gracia-Sancho, J. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.11.008 · Cited by 65
Self-citationRuan, B., Duan, J.-L., Xu, H., Tao, K.-S., Han, H., Dou, G.-R., & Wang, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.671081 · Cited by 67
“These results suggest that, following chronic liver injury, LSECs undergo a partial EndMT (Li et al., 2018; Piera-Velazquez and Jimenez, 2019) to form an intermediate phenotype of mesenchymal-like LSECs that produce a high amount of ECM with low migrating capacity.”
BackgroundSingle-nucleus RNA-seq2 reveals functional crosstalk between liver zonation and ploidy
Richter, M. L., Deligiannis, I. K., Yin, K., Danese, A., Lleshi, E., Coupland, P., Vallejos, C. A., Matchett, K. P., Henderson, N. C., Colome-Tatche, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24543-5 · Cited by 75
Best Practices and Progress in Precision-Cut Liver Slice Cultures
Dewyse, L., Reynaert, H., & van Grunsven, L. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137137 · Cited by 61
Liver X Receptors Regulate Cholesterol Metabolism and Immunity in Hepatic Nonparenchymal Cells
Endo‐Umeda, K., & Makishima, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205045 · Cited by 73
“When HSCs are activated by soluble factors including transforming growth factor β and platelet-derived growth factor, these cells transdifferentiate to myofibroblasts, a process that is marked by S100A6 expression, depletion of stored lipids, enhanced proliferation, and fibrogenic action mediated by the induction of α…”
BackgroundThe role of the innate immune system in the development and treatment of hepatocellular carcinoma
Roderburg, C., Wree, A., Demir, M., Schmelzle, M., & Tacke, F. (2020) · Hepatic Oncology · doi:10.2217/hep-2019-0007 · Cited by 72
Self-citationStiffness is associated with hepatic stellate cell heterogeneity during liver fibrosis
Kostallari, E., Wei, B., Sicard, D., Li, J., Cooper, S. A., Gao, J., Dehankar, M., Li, Y., Cao, S., Yin, M., et al. (2022) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00254.2021 · Cited by 65
Cheng, S., Zou, Y., Zhang, M., Bai, S., Tao, K., Wu, J., Shi, Y., Wu, Y., Lu, Y., He, K., et al. (2023) · MedComm · doi:10.1002/mco2.378 · Cited by 49
Extracellular vesicles: emerging roles, biomarkers and therapeutic strategies in fibrotic diseases
Zhu, J., Wang, S., Yang, D., Xu, W., & Qian, H. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01921-3 · Cited by 70
Li, J., Xing, S., Zhao, G., Zheng, M., Yang, X., Sun, J., Wen, J., & Liu, R. (2020) · BMC Genomics · doi:10.1186/s12864-020-07136-2 · Cited by 70
Mechanosignaling via Integrins: Pivotal Players in Liver Fibrosis Progression and Therapy
Sharip, A., & Kunz, J. (2025) · Cells · doi:10.3390/cells14040266 · Cited by 69
Zhang, W., Conway, S. J., Liu, Y., Snider, P. L., Chen, H., Gao, H., Liu, Y., Isidan, K., Lopez, K., Campaña, G., et al. (2021) · Cells · doi:10.3390/cells10082129 · Cited by 69
Yang, S., Liu, C., Jiang, M., Liu, X., Geng, L., Zhang, Y., Sun, S., Wang, K., Yin, J., Ma, S., et al. (2024) · Protein & Cell · doi:10.1093/procel/pwad039 · Cited by 62
“…for liver aging and its associated diseases, such as hepatocellular carcinoma (HCC), cirrhosis, liver fibrosis, and non-alcoholic steatohepatitis (Krenkel et al., 2019; Ramachandran et al., 2019; Ho et al., 2021; Wang et al., 2021b; Barreby et al., 2022; Hundertmark et al., 2022; Zhou et al.,…”
Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy
(2024) · doi:10.1146/annurev-pharmtox-020524-012013 · Cited by 64
The Origin and Fate of Liver Myofibroblasts
Kim, H. Y., Sakane, S., Eguileor, A., Carvalho Gontijo Weber, R., Lee, W., Liu, X., Lam, K., Ishizuka, K., Rosenthal, S. B., Diggle, K., et al. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.09.008 · Cited by 63
Morrison, J. K., DeRossi, C., Alter, I. L., Nayar, S., Giri, M., Zhang, C., Cho, J. H., & Chu, J. (2022) · Hepatology Communications · doi:10.1002/hep4.1930 · Cited by 62
Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis
Jangra, A., Kothari, A., Sarma, P., Medhi, B., Omar, B. J., & Kaushal, K. (2022) · Cells · doi:10.3390/cells11091500 · Cited by 58
“Next-generation sequencing has identified mutations in genes that are highly expressed in hepatic cells—such as ABCB4, ALDOB, GBE1, FAH, ASL, SLC25A13, and SERPINA1—which predispose the liver to fibrosis [65].”
BackgroundUnderstanding angiodiversity: insights from single cell biology
Jakab, M., & Augustin, H. G. (2020) · Development · doi:10.1242/dev.146621 · Cited by 54
The liver as an immunological barrier redefined by single‐cell analysis
Stamataki, Z., & Swadling, L. (2020) · Immunology · doi:10.1111/imm.13193 · Cited by 46
Harnessing metabolism of hepatic macrophages to aid liver regeneration
Liu, R., Scimeca, M., Sun, Q., Melino, G., Mauriello, A., Shao, C., Bernassola, F., Bove, P., Candi, E., Valentina, R., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06066-7 · Cited by 48
Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview
Pinheiro, D., Dias, I., Ribeiro Silva, K., Stumbo, A. C., Thole, A., Cortez, E., de Carvalho, L., Weiskirchen, R., & Carvalho, S. (2019) · Cells · doi:10.3390/cells8111339 · Cited by 46
“These activated cells are a heterogeneous population with different subsets that share the common expression of alpha-smooth muscle actin (α-SMA) and the marker S100A6 [5].”
BackgroundSelf-citationTrinh, V. Q.-H., Lee, T.-F., Lemoinne, S., Ray, K. C., Ybanez, M. D., Tsuchida, T., Carter, J. K., Agudo, J., Brown, B. D., Akat, K. M., et al. (2023) · Science Signaling · doi:10.1126/scisignal.adf6696 · Cited by 45
Merens, V., Knetemann, E., Gürbüz, E., Smet, V. D., Messaoudi, N., Reynaert, H., Verhulst, S., & van Grunsven, L. A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101223 · Cited by 44
The Potential Application of Magnetic Nanoparticles for Liver Fibrosis Theranostics
Eftekhari, A., Arjmand, A., Asheghvatan, A., Švajdlenková, H., Šauša, O., Abiyev, H., Ahmadian, E., Smutok, O. V., Khalilov, R. I., Kavetskyy, T. S., et al. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.674786 · Cited by 44
Johnson, N. D., Wu, X., Still, C. D., Chu, X., Petrick, A. T., Gerhard, G. S., Conneely, K. N., & DiStefano, J. K. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01129-y · Cited by 43
Molenaar, M. R., Haaker, M. W., Vaandrager, A. B., Houweling, M., & Helms, J. B. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.103042 · Cited by 42
Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications
Geng, Y., & Schwabe, R. F. (2025) · Hepatology · doi:10.1097/hep.0000000000001386 · Cited by 41
Mouse liver assembloids model periportal architecture and biliary fibrosis
Dowbaj, A. M., Sljukic, A., Niksic, A., Landerer, C., Delpierre, J., Yang, H., Lahree, A., Kühn, A. C., Beers, D., Byrne, H. M., et al. (2025) · Nature · doi:10.1038/s41586-025-09183-9 · Cited by 40
Human Liver Macrophage Subsets Defined by CD32
Wu, X., Hollingshead, N., Roberto, J., Knupp, A., Kenerson, H., Chen, A., Strickland, I., Horton, H., Yeung, R., Soysa, R., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02108 · Cited by 35
Gu, J., Chen, C., Wang, J., Chen, T., Yao, W., Yan, T., & Liu, Z. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2452848 · Cited by 39
Reyes-Avendaño, I., Reyes-Jiménez, E., González-García, K., Pérez-Figueroa, D. C., Baltiérrez‐Hoyos, R., Tapia-Pastrana, G., Sánchez-Chino, X. M., Villa‐Treviño, S., Arellanes‐Robledo, J., & Vásquez-Garzón, V. R. (2022) · Antioxidants · doi:10.3390/antiox11020358 · Cited by 37
“Liver fibrosis, which is characterized by aberrant accumulation of ECM components, constitutes a potent stimulus for the establishment of cancer [11].”
BackgroundInfluentialFibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
Subramanian, P., Hampe, J., Tacke, F., & Chavakis, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136996 · Cited by 37
“In NASH, HSCs contribute to approximately 80–95% of the ECM-producing MFBs, as shown in multiple mouse models of fibrosis [13].”
BackgroundInfluentialSelf-citationWen, M., Cai, G., Ye, J., Liu, X., Ding, H., & Zeng, H. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.35 · Cited by 36
“Single-cell transcriptomics sequencing has developed rapidly and been applied to various disciplines in recent years, and the method makes it possible to accurately characterize cell types and associated gene expression profiles in a mixture (18-20).”
MethodWang, Z., Xiang, Y., Kai, J., Wang, F., Wang, Z., Shao, J., Tan, S., Chen, A., Zhang, F., Wang, S., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117818 · Cited by 36
Mannaerts, I., Eysackers, N., van Os, E. A., Verhulst, S., Roosens, T., Smout, A., Hierlemann, A. R., Frey, O., Leite, S. B., & van Grunsven, L. A. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120335 · Cited by 36
Holistic characterization of single-hepatocyte transcriptome responses to high-fat diet
Park, S. R., Cho, C., Xi, J., Kang, H. M., & Lee, J. H. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00391.2020 · Cited by 35
Magnetic-Assisted Treatment of Liver Fibrosis
Levada, K. V., Omelyanchik, A. S., Rodionova, V. V., Weiskirchen, R., & Bartneck, M. (2019) · Cells · doi:10.3390/cells8101279 · Cited by 34
Self-citationTherapeutic modulation of the liver immune microenvironment
Tilg, H., Adolph, T. E., & Tacke, F. (2023) · Hepatology · doi:10.1097/hep.0000000000000386 · Cited by 31
Self-citationSalvianolic acid B inhibits hepatic stellate cell activation and liver fibrosis by targeting PDGFRβ
Liu, F., Li, S., Chen, P., Gu, Y., Wang, S., Wang, L., Chen, C., Wang, R., & Yuan, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110550 · Cited by 33
Otto, J., Verwaayen, A., Penners, C., Hundertmark, J., Lin, C., Kallen, C., Paffen, D., Otto, T., Berger, H., Tacke, F., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06077-4 · Cited by 33
Self-citationAzar, F., Courtet, K., Dekky, B., Bonnier, D., Dameron, O., Colige, A., Legagneux, V., & Théret, N. (2020) · Liver International · doi:10.1111/liv.14476 · Cited by 32
Luo, P., Chen, J., Zhang, Q., Xia, F., Wang, C., Bai, Y., Tang, H., Liu, D., Gu, L., Du, Q., et al. (2022) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbac023 · Cited by 32
Plasticity, heterogeneity, and multifunctionality of hepatic stellate cells in liver pathophysiology
Du, K., Jun, J. H., Dutta, R. K., & Diehl, A. M. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000411 · Cited by 31
“Krenkel et al [41] reported the first scRNA-seq analysis of activated HSCs from CCl 4 -injured liver.”
BackgroundMethodInfluentialDissecting the mechanisms of MASLD fibrosis in the era of single-cell and spatial omics
Colella, F., Henderson, N. C., & Ramachandran, P. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186421 · Cited by 31
Control of Tissue Fibrosis by 5-Methoxytryptophan, an Innate Anti-Inflammatory Metabolite
Wu, K. K. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.759199 · Cited by 31
“Advances in single cell analytic techniques coupled with RNA sequencing and transcriptomes, have shed lights on heterogeneity of resident fibroblasts in various organs and the involvement of a subset of fibroblasts destined to be differentiated into myofibroblasts (Dobie et al., 2019; Krenkel et al., 2019; Ramachandra…”
BackgroundOderberg, I. M., & Goessling, W. (2023) · JCI Insight · doi:10.1172/jci.insight.163929 · Cited by 31
Hajiabadi, S., Alidadi, S., Farahi, Z. M., Seno, M. M. G., Farzin, H., & Haghparast, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1258691 · Cited by 31
Gomisin D alleviates liver fibrosis through targeting PDGFRβ in hepatic stellate cells
Wang, R., Liu, F., Chen, P., Li, S., Gu, Y., Wang, L., Chen, C., & Yuan, Y. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123639 · Cited by 30
Gong, J., Gong, H., Liu, Y., Tao, X., & Zhang, H. (2022) · Bioengineered · doi:10.1080/21655979.2021.2024385 · Cited by 29
“Notably, the damage of the liver often leads to the production of various cellular inflammatory factors, which in turn activates HSCs and transforms it into MFB, thereby starting to express a large number of musculo-skeletal proteins, such as α-SMA [39].”
BackgroundS100A6 Protein—Expression and Function in Norm and Pathology
Leśniak, W., & Filipek, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021341 · Cited by 29
Kohlhepp, M. S., Liu, H., Tacke, F., & Guillot, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1129831 · Cited by 27
“(Krenkel et al., 2019; Ramachandran et al., 2019; Ramachandran et al., 2020; Cheng et al., 2021; Guilliams et al., 2022; Lee et al., 2022; Tada et al., 2022) Importantly, most macrophage-derived cytokines or macrophage polarizing factors affectmultiple cell populations.”
BackgroundSelf-citation
Metadata
- Authors
- Krenkel, O., Hundertmark, J., Ritz, T., Weiskirchen, R., & Tacke, F.
- Affiliations
- Boehringer Ingelheim (Germany) (DE)
- Universitätsklinikum Aachen (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Corresponding author
- Tacke, Frank
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-05-24
- Volume
- 8
- Issue
- 5
- Pages
- 503
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC6562512
- OpenAlex
- W2945705065
- Cited by
- 241
- References
- 20
- Citations by year
- 2026: 19 · 2025: 41 · 2024: 23 · 2023: 40 · 2022: 38 · 2021: 37 · 2020: 33 · 2019: 10
- FWCI
- 18.80
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Deutsche Forschungsgemeinschaft (SFB/TRR57, Ta434/3-1, Ta434/5-1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- hepatic stellate cells, myofibroblasts, liver fibrosis, cellular heterogeneity, hepatic stellate cell activation, transdifferentiation, S100A6, PDGFRβ, alpha-smooth muscle actin, collagen, carbon tetrachloride, chemokines, single-cell RNA sequencing
- MeSH terms
- S100 Calcium Binding Protein A6, Actins, Animals, Base Sequence, Carbon Tetrachloride, Cells, Cultured, Collagen, Disease Models, Animal, Liver, Liver Cirrhosis, Mice, Inbred C57BL, Gene Expression, Sequence Analysis, RNA, Genetic Heterogeneity, Cell Cycle Proteins, Chemokines, Receptor, Platelet-Derived Growth Factor beta, Mice, Hepatic Stellate Cells, Myofibroblasts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.